Direkt zum Inhalt
Merck
  • Effects of chronic treatments with SM-9018, a potential atypical neuroleptic, on behavioral dopaminergic and serotonergic sensitivities in rats.

Effects of chronic treatments with SM-9018, a potential atypical neuroleptic, on behavioral dopaminergic and serotonergic sensitivities in rats.

General pharmacology (1995-05-01)
Y Ohno, K Ishida, T Ishibashi, K Ikeda, T Kato, M Nakamura
ZUSAMMENFASSUNG

1. Changes in behavioral dopaminergic and serotonergic sensitivities were studied in rats after withdrawal of the chronic treatments with SM-9018 (0.1 mg/kg/day), a potential atypical neuroleptic, and with haloperidol (0.3 mg/kg/day) using continuous infusion pumps. 2. Administration of SM-9018 inhibited the rat locomotor activities to an extent similar to that of haloperidol during the course of the 2 weeks treatment. 3. The incidence of the apomorphine-induced stereotyped behaviors (e.g., sniffing, chewing, licking and biting) was negligibly affected by SM-9018 treatment, but was markedly enhanced by haloperidol treatment. 4. The incidence of the 5-hydroxytryptophan-induced wet dog shakes and 8-hydroxy-2-(di-n-propyl-amino)tetralin-induced flat body posture was unaffected by either treatment with SM-9018 or haloperidol. 5. These findings suggest that SM-9018 is weaker than haloperidol in inducing the behavioral dopaminergic hypersensitivity after its chronic treatment and has a lower propensity to cause tardive dyskinesia.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Perospirone hydrochloride, ≥98% (HPLC)